This study investigated the presence of mRNA coding for interferon gamma
corresponding to amino acids 3-21, 31-49, and 202-220 of A-gliadin whose coeliac toxicity is supported by earlier in vitro studies.67 These peptides and gliadin were used to challenge four coeliac patients in remission. 8 Jejunal biopsy specimens were taken before and at hourly intervals for six hours after the infusions. Morphometric measurements and intraepithelial lymphocyte counts have shown that gliadin and the oligopeptide whose sequence corresponds to amino acids 31-49 of A-gliadin are both toxic in vivo within four hours of challenge but there was no evidence of toxicity of the peptide with residues 3-21. Evidence from two previous in vivo studies using the peptide 202-220 is equivocal8 9 house' using a Beckman synthesiser. Cytokine detection was achieved using a cocktail of three probes for each cytokine, each 30 bases long, with cDNA sequences coded by three different exon regions of the IFN-y, TNFa, IL6, and IL2 genes. Table II lists the probes used in this study and their sequences. Four pmol of each oligonucleotide were labelled by the addition of an of35S dATP 'tail' to the 3' termini using terminal deoxynucleotidyl transferase, according to the supplier's protocol (Promega). After the labelling reaction, probes were purified by filtration through Sephadex G-50 DNA grade columns (Pharmacia) and their specific activity measured using a Rackbeta liquid scintillation counter. The specific activity of the probes was greater than 1 X 108 cpm/,ug.
Probe specificity Specificity of the probes was confirmed by northern blotting of mRNA coding for IFNy, TNFa, IL6, and IL2, isolated from blood mononuclear cells that had been cultured in the presence of 1 ,ig/ml phytohaemagglutinin (PHA) or 10 ,ig/ml concanavalin A (Con A) as previously described. ' (Table II) , were used as negative controls. As a positive control, an oligo dT probe was used for the detection oftotal mRNA.
Quantification and statistical analysis
All assessments were performed blind to patient identity and peptide. The number of positive cells within the lamina propria were counted per unit area by using an eyepiece graticule (1 mm2) under X400 magnification. At least five consecutive areas in the lamina propria, within and below the villi going to the deeper lamina propria were counted for each probe. Counts were expressed as positive cells in the lamina propria per unit area (0.0025 mm2) and referred to in the text as median (range). For each patient, the Wilcoxon rank sum test for unpaired data was used to compare the values at each time point after the challenge with those obtained before the challenge. Significance was set at p<0O05.
Results Figure 1 shows the distribution of TNFa mRNA expressing cells within the jejunal mucosa before the gliadin challenge and shows the distribution after four hours. Similar changes were seen with the other cytokine probes. The jejunal mucosa of all the patients studied, contained cells expressing mRNA for IFNy, TNFa, IL6, and IL2. The positive signal was located mainly in the lamina propria, with little or no signal in the surface epithelium.
Gliadin challenge Increased hybridisation signal was seen in the Peptide challenge The number of cells expressing cytokine mRNA was also measured in the lamina propria of each patient, before and four hours after challenge with each of the three oligopeptides studied (Table III) . After challenge with peptide A, patients 3 and 4 showed a significant increase in the number of cells expressing mRNA for IFNy, TNFa, IL2, and IL6, but patients 1 and 2 showed a significant increase in IFNy and IL6 mRNA expressing cells only.
Challenge with peptide B resulted in increased numbers of TNFoL mRNA expressing cells in the lamina propria of patient 3 only, but caused no changes in the other patients.
No response was seen in any of the patients with peptide C. Figure 4 shows the typical appearance of a section of jejunal mucosa, four hours after gliadin challenge, after hybridisation with the 19 20 Previous studies have shown increased expression of IFNy mRNA in untreated coeliac patients compared with treated patients and controls and suggests an association between the observed morphological changes and mucosal T cell activation.'7 IFNy in combination with TNFac has been shown to increase expression of MIHC class I and II21
Controls
and adhesion molecules within intestinal tissue.22 Both cytokines can destroy target tissues of known autoimmune diseases23 and also reduce the epithelial barrier function of the human colon carcinoma cell line HT29. 24 25 The results of this study complement our previous findings,8 by showing increased cytokine expression in the lamina propria of treated coeliac patients, four hours after gliadin challenge, which coincides with significant histological changes in the small intestinal mucosa of these patients. It was shown that the synthetic oligopeptide corresponding to residues 31-49 ofA-gliadin (peptide A) displays in vivo toxicity in these patients with treated coeliac disease. We have now shown that the lamina propria of the same patients contained increased numbers of cells expressing cytokine mRNA in response to peptide A. Other studies have shown that peptide A is recognised by gliadin specific T cell clones when presented by HLA-DQ2 molecules,26 which is present in over 95% of patients with coeliac disease.27 Therefore, taken together these findings provide strong support for the role of peptide A as a coeliac toxic fragment of A-gliadin.
An association between histological changes and cytokine expression was seen in one of four patients studied after challenge with peptide B. In this patient the peptide caused a significant reduction both in villous height to crypt depth ratio and enterocyte height, but not an increase in intraepithelial lymphocyte numbers. It is possible that the production of these cytokines can either cause direct damage to the mucosa or lead to increased production of other inflammatory or toxic mediators, or both that are responsible for the histological changes in coeliac disease. An interesting finding was that, after challenge with peptide A, the number of IFNy mRNA expressing cells increased in all four patients studied. This could suggest that this cytokine is primarily produced during the immune response acting to propogate the T cell mediated immune response and the release of other inflammatory cytokines. The hypothesis that cytokines are capable of causing direct tissue damage could be confirmed by studying their effect on epithelial differentiation and proliferation in human jejunum organ culture. Recent data using such a system have shown that supernatants from gliadin activated HLA DQ2 restricted T lymphocyte clones cause epithelial cell toxicity similar to that seen in untreated coeliac mucosa and this effect may be blocked by anti-IFNy antibodies.31
Our findings suggest that the expression of cytokine mRNA by lamina propria cells may reflect a process of cellular activation during the development of coeliac disease. It is possible that understanding the production of cytokines and its regulation within the small intestinal mucosa may lead to the recognition of new approaches to treatment of coeliac disease.
